Articles with public access mandates - Marcelo V. NegraoLearn more
Not available anywhere: 1
Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection
N Deboever, DJ McGrail, Y Lee, HT Tran, KG Mitchell, MB Antonoff, ...
Lung Cancer 164, 69-75, 2022
Mandates: US National Institutes of Health
Available somewhere: 35
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
X Le, S Puri, MV Negrao, MB Nilsson, J Robichaux, T Boyle, JK Hicks, ...
Clinical Cancer Research 24 (24), 6195-6203, 2018
Mandates: US National Institutes of Health
Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity
JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ...
Cancer Cell 36 (4), 444-457. e7, 2019
Mandates: US Department of Defense, US National Institutes of Health
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
MV Negrao, F Skoulidis, M Montesion, K Schulze, I Bara, V Shen, H Xu, ...
Journal for immunotherapy of cancer 9 (8), 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC
L Hong, MV Negrao, SS Dibaj, R Chen, A Reuben, JM Bohac, X Liu, ...
Journal of Thoracic Oncology 15 (9), 1449-1459, 2020
Mandates: Cancer Prevention Research Institute of Texas, USA
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
MB Nilsson, H Sun, J Robichaux, M Pfeifer, U McDermott, J Travers, ...
Science translational medicine 12 (559), eaaz4589, 2020
Mandates: US National Institutes of Health, LUNGevity Foundation, USA
STING pathway expression identifies NSCLC with an immune-responsive phenotype
CM Della Corte, T Sen, CM Gay, K Ramkumar, L Diao, RJ Cardnell, ...
Journal of Thoracic Oncology 15 (5), 777-791, 2020
Mandates: US Department of Defense, US National Institutes of Health, Lung Cancer …
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
T Cascone, CH Leung, A Weissferdt, A Pataer, BW Carter, MCB Godoy, ...
Nature medicine 29 (3), 593-604, 2023
Mandates: US National Institutes of Health
Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial
YY Elamin, JP Robichaux, BW Carter, M Altan, DL Gibbons, FV Fossella, ...
Journal of Clinical Oncology 40 (7), 702-709, 2022
Mandates: US National Institutes of Health, Lung Cancer Research Foundation, USA
Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target
X Le, MV Negrao, A Reuben, L Federico, L Diao, D McGrail, M Nilsson, ...
Journal of thoracic oncology 16 (4), 583-600, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer
L Federico, DJ McGrail, SE Bentebibel, C Haymaker, A Ravelli, MA Forget, ...
Annals of Oncology 33 (1), 42-56, 2022
Mandates: US National Institutes of Health, Fonds de recherche du Québec - Santé
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
YY Elamin, JP Robichaux, BW Carter, M Altan, H Tran, DL Gibbons, ...
Cancer Cell 40 (7), 754-767. e6, 2022
Mandates: US National Institutes of Health, Lung Cancer Research Foundation, USA …
Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC
PO Gaudreau, MV Negrao, KG Mitchell, A Reuben, EM Corsini, J Li, ...
Journal of Thoracic Oncology 16 (1), 127-139, 2021
Mandates: US National Institutes of Health, Fonds de recherche du Québec - Santé …
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
MV Negrao, HA Araujo, G Lamberti, AJ Cooper, NS Akhave, T Zhou, ...
Cancer discovery 13 (7), 1556-1571, 2023
Mandates: US National Institutes of Health, V Foundation, USA
Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations
MV Negrao, VM Raymond, RB Lanman, JP Robichaux, J He, MB Nilsson, ...
Journal of Thoracic Oncology 15 (10), 1611-1623, 2020
Mandates: US National Institutes of Health
STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition
P Sitthideatphaiboon, A Galan-Cobo, MV Negrao, X Qu, A Poteete, ...
Clinical Cancer Research 27 (6), 1720-1733, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer
B Sepesi, N Zhou, WN William Jr, HY Lin, CH Leung, A Weissferdt, ...
The Journal of thoracic and cardiovascular surgery 164 (5), 1327-1337, 2022
Mandates: US National Institutes of Health
Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non–small-cell lung cancer (NSCLC)
YY Elamin, DR Gomez, MB Antonoff, JP Robichaux, H Tran, MK Shorter, ...
Clinical Lung Cancer 20 (1), 43-47, 2019
Mandates: US National Institutes of Health
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
B Ricciuti, JV Alessi, A Elkrief, X Wang, A Cortellini, YY Li, VR Vaz, ...
Annals of Oncology 33 (10), 1029-1040, 2022
Mandates: US National Institutes of Health
Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a …
KG Mitchell, L Diao, T Karpinets, MV Negrao, HT Tran, ER Parra, ...
Journal for immunotherapy of cancer 8 (1), 2020
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program